Clinical Trial Update: A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of Mipasetamab Uzoptirine (ADCT-601) in participants with solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Mipasetamab Uzoptirine (ADCT-601)

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: Advanced Solid Tumors | Phase 1 | Status: TERMINATED